BioVie Inc (BIVI) USD0.0001

Sell:$0.80Buy:$0.84$0.14 (14.29%)

Prices delayed by at least 15 minutes
Sell:$0.80
Buy:$0.84
Change:$0.14 (14.29%)
Prices delayed by at least 15 minutes
Sell:$0.80
Buy:$0.84
Change:$0.14 (14.29%)
Prices delayed by at least 15 minutes

Company Information

About this company

BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Key people

Viet Cuong Do
President, Chief Executive Officer, Director
Joanne Wendy Kim
Chief Financial Officer, Corporate Secretary
Joseph M. Palumbo
Chief Medical Officer
James Lang
Independent Chairman of the Board
Richard Jay Berman
Independent Director
Sigmund Rogich
Independent Director
Michael Edward Sherman
Independent Director
Click to see more

Key facts

  • EPIC
    BIVI
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09074F4054
  • Market cap
    $18.64m
  • Employees
    14
  • Shares in issue
    18.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.